viral
diseas
remain
major
caus
death
worldwid
despit
advanc
vaccin
antivir
drug
technolog
year
three
million
peopl
die
rang
viral
infect
predomin
virus
includ
human
immunodefici
viru
hepat
virus
gastrointestin
respiratori
virus
ever
robust
easili
mobilis
costeffect
antivir
strategi
need
combat
known
emerg
diseas
threat
rna
interfer
small
interf
si
rna
initi
hail
magic
bullet
due
abil
inhibit
synthesi
protein
via
degrad
complementari
messeng
rna
sequenc
particular
interest
potenti
attenu
viral
mrna
contribut
pathogenesi
diseas
abl
target
vaccin
antivir
drug
howev
soon
discov
deliveri
activ
sirna
molecul
infect
site
vivo
consider
difficult
anticip
due
number
physiolog
barrier
bodi
spur
new
wave
investig
nucleic
acid
deliveri
vehicl
could
facilit
safe
target
effect
administr
sirna
therapi
amongst
cation
polym
deliveri
vehicl
emerg
promis
candid
lowcost
easi
produc
industri
scale
bind
sirna
nonspecif
electrostat
interact
nanoparticl
np
function
design
target
infect
site
improv
uptak
infect
cell
releas
articl
part
topic
collect
sirna
insid
endosom
facilit
deliveri
cell
cytoplasm
may
also
ad
benefit
act
adjuv
chapter
provid
background
around
problem
associ
translat
sirna
antivir
treatment
review
progress
made
nucleic
acid
therapeut
discuss
current
method
progress
overcom
challeng
also
address
import
combin
physicochem
characteris
np
vitro
vivo
data
keyword
polym
rna
interfer
antivir
therapeut
nucleic
acid
therapeut
quantit
nanomechan
atom
forc
microscopi
physicochem
characteris
centuri
infecti
diseas
major
caus
human
morbid
mortal
today
cardiovascular
diseas
cancer
highestr
killer
howev
viral
diseas
lower
respiratori
tract
infect
hivaid
measl
hepat
virus
diarrhoeal
diseas
still
remain
among
lead
caus
death
disabl
particularli
develop
countri
http
www
whointtopicsmortalityen
fig
combin
mortal
rate
associ
viral
infect
total
three
million
death
per
year
backdrop
establish
persist
viral
infect
challeng
manag
threat
new
epidem
old
new
infecti
diseas
fig
exampl
includ
recent
outbreak
new
strain
ebola
viru
swept
africa
kill
least
peopl
swine
flu
epidem
spread
around
world
april
decemb
result
estim
death
emerg
new
highli
pathogen
strain
zika
viru
south
america
caus
microcephali
newborn
alreadi
spread
countri
includ
usa
past
centuri
also
observ
emerg
numer
new
zoonot
infect
signific
impact
global
burden
diseas
fig
particular
highli
pathogen
avian
influenza
strain
origin
poultri
contribut
total
laboratoryconfirm
case
human
death
sinc
exampl
zoonot
spillov
event
includ
emerg
new
virus
origin
bat
henipavirus
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
outbreak
high
mortal
rate
continu
threaten
commun
global
viral
infect
agricultur
industri
also
major
concern
infect
livestock
act
reservoir
potenti
zoonot
pandem
addit
infecti
outbreak
crop
farm
anim
pose
signific
threat
econom
food
secur
move
futur
increas
socioeconom
burden
diseas
unten
thu
global
need
intervent
strategi
conserv
maintain
human
plant
anim
health
secur
econom
welfar
develop
therapeut
nine
highestimpact
human
diseas
progress
rapidli
past
year
lead
commerci
translat
antivir
drug
fig
rang
differ
target
approach
utilis
block
infect
cycl
sever
virus
includ
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
herpesviru
human
cytomegaloviru
varicellazost
viru
respiratori
syncyti
viru
influenza
viru
extern
anogenit
wart
caus
human
papillomaviru
date
combin
treatment
prevent
strategi
save
million
live
addit
gener
revenu
predict
reach
billion
global
antivir
market
despit
fervent
effort
field
antivir
research
develop
mani
persist
newli
emerg
viral
diseas
human
livestock
anim
still
lowcost
safe
readili
mobilis
treatment
vaccin
global
health
left
increasingli
vulner
posit
result
combin
factor
includ
increas
number
emerg
diseas
outbreak
limit
avail
effect
drug
vaccin
candid
develop
resist
strain
pathogen
diseas
vector
carri
virus
previous
uninfect
area
eas
movement
infect
host
via
air
travel
declin
rate
vaccin
fig
thu
essenti
move
swiftli
toward
establish
improv
detect
vaccin
treatment
strategi
nucleic
acid
therapi
investig
altern
treatment
solut
wide
rang
infecti
diseas
mani
becom
resist
standard
drug
intervent
longer
respond
reliabl
tradit
clinic
manag
strategi
three
main
approach
nucleic
acid
therapi
current
investig
gene
addit
host
genom
supplement
exogen
genet
materi
result
overexpress
natur
occur
immun
factor
mount
improv
immun
defenc
pathogen
antisens
oligonucleotid
aso
aso
short
singlestrand
dna
molecul
hybridis
uniqu
target
sequenc
within
viral
messeng
rna
express
host
cell
thu
modul
gene
express
rna
interfer
rnai
method
similar
aso
regul
howev
gene
express
alter
small
interf
si
rna
sirna
class
doublestrand
rna
base
pair
length
use
microrna
pathway
bind
complementari
nucleotid
sequenc
abl
direct
degrad
complementari
mrna
henc
regul
express
protein
product
first
gene
addit
therapi
treatment
licens
china
treat
head
neck
squamou
cell
carcinoma
treatment
adenovirusbas
medicin
deliv
function
copi
gene
via
recombin
gendicin
shenzhen
sibiono
gene
technolog
sinc
three
gene
addit
therapeut
approv
market
glybera
approv
european
union
treatment
lipoprotein
lipas
defici
adenoassoci
viral
vector
engin
express
lipoprotein
lipas
muscl
joint
advisori
committe
us
food
drug
administr
fda
vote
approv
talimogen
laherparepvec
tvec
final
approv
grant
fda
attenu
replicationcompet
oncolyt
herp
simplex
viru
engin
induc
express
immunostimulatori
cytokin
granulocytemacrophag
colonystimul
factor
treatment
melanoma
final
glaxosmithklin
anticip
immin
releas
strimv
gamma
retrovirusmedi
ex
vivo
gene
therapi
late
strimv
design
treat
rare
sever
combin
immun
defici
disord
aris
adenosin
deaminas
defici
whilst
main
focu
gene
therapi
date
host
genet
disord
benefit
type
therapeut
strategi
limit
mutat
human
gene
field
expand
type
gene
therapi
may
also
use
attenu
inhibit
spread
infecti
pathogen
includ
virus
fda
also
approv
three
aso
drug
fomivirsen
phosphorothioatemodifi
oligodeoxynucleotid
target
major
immediateearli
region
protein
human
cytomegaloviru
licens
fda
august
intraocular
administr
fomivirsen
use
treatment
cytomegaloviru
retin
immunocompromis
patient
includ
aid
fda
approv
grant
aso
treatment
mipomersen
treatment
homozyg
famili
hypercholesterolaemia
rare
genet
disord
lead
excess
level
apolipoprotein
b
apob
lowdens
lipoprotein
cholesterol
result
prematur
cardiovascular
diseas
howev
side
effect
treatment
administr
reserv
sever
case
disord
final
alicaforsen
use
treatment
inflammatori
bowel
diseas
caus
ulcer
coliti
fda
design
therapi
fasttrack
candid
unmet
medic
need
orphan
drug
categori
despit
translat
success
gene
addit
aso
therapi
sirnabas
therapeut
current
market
due
limit
success
clinic
trial
factor
contribut
failur
therapeut
includ
instabl
sirna
rapid
clearanc
bodi
inabl
effici
enter
target
cell
inabl
reach
cell
cytoplasm
overcom
deliveri
challeng
particular
effort
focuss
develop
suitabl
nanoparticl
np
deliveri
vehicl
protect
facilit
sirna
deliveri
target
site
action
histori
discoveri
develop
sirnabas
therapi
success
obstacl
associ
strategi
review
greater
detail
rna
interfer
rnai
believ
emerg
antivir
defenc
system
eukaryot
wherebi
invad
viral
rna
genom
recognis
degrad
order
inhibit
viru
replic
process
rnai
first
observ
inhibit
rna
transcript
express
virusinfect
transgen
plant
model
propos
waterhous
et
al
hypothesis
observ
posttranscript
gene
silenc
mediat
rnadepend
mechan
present
cell
cytoplasm
requir
doublestrand
ds
rna
templat
sequencespecif
recognit
degrad
foreign
mrna
transcript
around
time
research
group
note
similar
mechan
altern
eukaryot
system
fig
fire
mello
publish
analog
find
nematod
caenorhabd
elegan
inject
nematod
doublestrand
rna
dsrna
target
gene
elimin
express
endogen
mrna
transcript
caus
transcript
suppress
proven
due
hybridis
inject
dsrna
complementari
endogen
mrna
hybridis
event
ultim
result
mrna
cleavag
dsrnadepend
rna
polymeras
inhibit
protein
product
work
confirm
molecular
mechan
underpin
phenotyp
observ
made
waterhous
et
al
thu
term
rna
interfer
coin
result
rapid
advanc
gene
technolog
follow
groundbreak
research
fire
mello
award
nobel
prize
physiolog
medicin
shortest
period
ever
discoveri
award
rnai
seiz
world
attent
offer
way
attenu
product
protein
within
cell
includ
associ
diseas
state
sinc
revolutionari
discoveri
stagger
amount
research
undertaken
har
molecular
pathway
therapeut
strategi
treatment
cancer
genet
disord
viral
infect
know
rna
interfer
process
adapt
evolutionari
time
contribut
regul
eukaryot
protein
synthesi
rnai
pathway
identifi
eukaryot
similarli
eukaryot
encod
varieti
short
rna
strand
typic
refer
microrna
mirna
destin
translat
secondari
level
transcript
control
rnai
discoveri
timelin
first
indic
sens
rna
effect
antisens
rna
suppress
gene
express
c
elegan
waterhous
describ
process
rnai
plant
whilst
fire
mello
coin
term
rna
interfer
first
evid
rnai
mechan
present
mammal
rnai
begin
show
promis
clinic
progress
total
regist
sirna
clinic
trial
rnai
therapeut
phase
phase
iii
trial
involv
sirna
np
formul
http
clinicaltrialsgov
futur
end
alnylam
pharmaceut
still
largest
rnaided
compani
expect
achiev
compani
profil
three
market
product
ten
rnai
therapeut
clinic
programsinclud
four
late
stage
develop
http
wwwalnylamcom
mirna
transcrib
nucleu
either
primari
pri
mirna
contain
nucleotid
long
stemloop
structur
encod
within
mrna
intron
fig
two
protein
rnase
iii
enzym
drosha
dsrna
bind
protein
make
microprocessor
complex
cleav
primirna
precursor
pre
mirna
premirna
transport
cytoplasm
nucleocytoplasm
transport
factor
matur
mirna
product
requir
final
cleavag
step
remov
loop
structur
produc
short
dsrna
perform
anoth
rnase
iii
enzym
dicer
mirna
associ
multiprotein
rnainduc
silenc
complex
risc
compris
argonaut
dicer
human
immunodefici
viru
transactiv
respons
rnabind
protein
mirna
unwound
guid
mirna
strand
integr
risc
complex
remain
strand
passeng
strand
degrad
risc
complex
substrat
riscbound
mirna
recognis
bind
complementari
mrna
viral
rna
host
cell
cytoplasm
risc
cleav
target
mrna
posit
face
nucleotid
sirna
lead
degrad
mrna
inhibit
subsequ
protein
product
comprehens
review
process
see
follow
discoveri
rnai
pathway
c
elegan
research
found
introduct
exogen
synthet
synthesis
sirna
molecul
cell
could
also
enabl
specif
target
mrna
transcript
silenc
tabl
plasmid
viru
vectorbas
deliveri
sirna
also
explor
fig
tabl
wherebi
sirna
produc
short
hairpin
sh
rna
shrnamir
mimic
natur
mirna
structur
multipl
hairpin
nucleu
enter
pathway
use
exit
nucleu
fig
abil
synthet
sirna
select
target
degrad
mrna
pave
way
novel
class
antivir
therapeut
capabl
inhibit
protein
viral
product
suppress
viral
infect
multipl
studi
shown
sirna
inhibit
wide
rang
virus
tabl
virus
mrna
step
replic
cycl
product
viral
protein
therefor
even
virus
dnabas
genom
target
fig
tabl
attract
sirna
uniqu
antivir
therapeut
synthet
sirna
rapidli
develop
viru
provid
sequenc
viral
rna
known
furthermor
conserv
target
sequenc
identifi
sever
viru
famili
thu
offer
promis
develop
panfamili
therapeut
strategi
could
provid
protect
multipl
virus
one
therapeut
advanc
highthroughput
sequenc
technolog
allow
rapid
adapt
target
sirna
therapi
emerg
new
viral
strain
virus
confer
drug
resist
utmost
import
outbreak
respons
manag
effort
speed
therapeut
picornavirida
positivesens
singlestrand
rna
genom
protein
untransl
region
develop
produc
larg
quantiti
treatment
often
major
bottleneck
manag
strategi
industri
also
recognis
need
made
fast
translat
larg
quantiti
therapeut
product
feasibl
instanc
case
recent
ebola
outbreak
newli
design
sirna
target
emerg
ebola
viru
makona
strain
produc
incorpor
lipid
np
system
within
week
deploy
compassion
use
outbreak
remark
compar
averag
month
take
produc
new
vaccin
howev
despit
promis
sirnabas
therapi
hold
treatment
viral
diseas
limit
success
clinic
trial
restrict
product
market
sirna
therapeut
understand
overcom
limit
barrier
sirna
deliveri
therefor
essenti
maximis
potenti
novel
therapeut
approach
modern
medicin
multipl
factor
contribut
main
obstacl
effici
sirna
deliveri
fig
key
obstacl
list
sirna
highli
unstabl
bodili
fluid
due
rnase
present
serum
mucos
layer
rapidli
degrad
sirna
phosphat
backbon
thu
effici
protect
rnase
must
sought
due
small
size
less
nm
sirna
rapidli
clear
via
renal
filtrat
time
higher
concentr
sirna
observ
kidney
excret
urin
compar
tissu
h
follow
intraven
inject
anoth
studi
sirna
dose
found
kidney
min
viral
infect
rare
enhanc
permeabl
retent
epr
effect
infect
tissu
contrast
deliveri
model
cancer
therapeut
combin
poor
lymphat
drainag
leaki
vasculatur
allow
accumul
therapeut
target
site
thu
import
find
way
increas
circul
time
serum
sirna
success
deliveri
strategi
fig
obstacl
uptak
nake
sirna
degrad
sirna
nucleas
serum
b
clearanc
liver
kidney
reticuloendotheli
system
c
poor
tissu
permeabl
poor
cell
uptak
due
neg
charg
cell
membran
sirna
e
ineffici
releas
endosom
nucleic
acid
phosphat
backbon
sirna
result
overal
neg
charg
particl
fig
outer
leaflet
cell
membran
also
carri
slight
neg
charg
therefor
repel
nake
sirna
bind
effici
enter
cell
order
overcom
problem
neg
charg
sirna
shield
allow
effici
transport
across
cell
membran
typic
sirna
therapeut
cross
cell
membran
via
endocyt
pathway
thu
must
escap
endosom
interact
risc
complex
cytoplasm
effect
deliveri
sirna
must
therefor
abl
effici
disrupt
endosom
order
deliv
sirna
cytoplasm
prior
transport
degrad
lysosom
therefor
unless
deliv
directli
site
treatment
nake
sirna
ineffect
therapeut
signific
work
undertaken
toward
develop
carrier
rnai
tabl
summaris
advantag
disadvantag
differ
method
comprehens
review
see
advanc
method
current
clinic
trial
describ
overcom
issu
serum
degrad
chemic
modif
sirna
nucleotid
investig
oh
ribonucleotid
distinguish
rna
dna
catalyt
target
rnase
fig
modif
nucleotid
oposit
sugar
shown
increas
sirna
stabil
rnase
adjust
includ
phosphorothio
modif
nonbridg
oxygen
phosphat
linkag
replac
sulfur
atom
omethoxyethyl
omo
fluoro
f
substitut
imped
rnase
activ
lock
nucleic
acid
lna
lock
group
carbon
group
inhibit
rnase
degrad
fig
advanc
antivir
sirna
clinic
trial
use
modifi
sirna
conduct
alnylam
pharmaceut
treat
respiratori
syncyti
viru
rsv
use
omoemodifi
antirsv
sirna
fig
first
trial
safeti
pharmacokinet
studi
analys
singl
dose
mg
multipl
dose
day
none
adult
cohort
show
advers
alnylam
follow
human
trial
healthi
human
subject
infect
nasal
wash
assay
antivir
effect
clinic
efficaci
group
saw
reduct
rate
infect
trend
toward
lower
viral
titr
demonstr
first
time
respiratorydeliv
sirna
could
significantli
reduc
rsv
infect
two
trial
phase
iia
b
assess
abil
inhibit
bronchiol
obliteran
syndrom
follow
rsv
infect
lung
transplant
recipi
trial
result
signific
reduct
present
bronchiol
obliteran
syndrom
rsv
infect
lung
transplant
patient
result
led
alnylam
discuss
strategi
move
drug
forward
fda
registr
alnylam
also
conduct
clinic
trial
sirna
directli
conjug
asialoglycoprotein
receptor
ligand
nacetylgalactosamin
galnac
galnacconjug
transthyretin
ttr
sirna
enter
phase
iii
trial
ttr
knockdown
serum
treatment
ttrmediat
amyloidosi
second
candid
treatment
haemophilia
relat
blood
disord
target
antithrombin
recent
press
releas
alnylam
indic
knockdown
serum
achiev
phase
trial
http
wwwalnylamcomcapella
commerci
avail
lipidbas
transfect
reagent
lipofectamin
tm
fugen
use
vitro
studi
sever
occas
reagent
demonstr
success
deliveri
sirna
target
influenza
protect
lethal
challeng
anim
model
howev
due
toxic
translat
agent
viabl
sirna
carrier
applic
human
explor
nonetheless
signific
bodi
literatur
avail
demonstr
lipidbas
system
may
suitabl
therapeut
sirna
deliveri
human
fig
studi
comprehens
review
ebola
outbreak
exampl
clinic
trial
conduct
antiebola
sirnalipidbound
small
interf
rna
sirna
known
administr
dose
mgkg
per
day
intraven
infus
day
adult
patient
sever
ebola
viru
diseas
improv
surviv
compar
histor
control
despit
promis
result
experiment
infect
nonhuman
primat
model
attribut
fact
deliveri
occur
advanc
diseas
stage
time
viral
load
exist
organ
damag
overwhelm
addit
obstacl
pertain
time
therapeut
administr
lipid
nanocarri
often
tendenc
aggreg
activ
ingredi
degrad
storag
make
largescal
manufactur
cold
chain
storag
difficult
particularli
remot
arid
set
commonli
use
viral
vector
includ
adenoviru
lentiviru
retrovirus
fig
retrovirus
abil
integr
host
genom
allow
continu
express
rnai
treatment
whilst
adenovirus
viral
vector
given
signific
hope
longlast
treatment
hiv
hepat
b
c
clinic
trial
sirna
deliveri
use
viral
vector
conduct
hiv
patient
particip
underw
transplant
lentiviraltransform
haematopoiet
progenitor
cell
design
express
three
antihiv
sirna
would
theoret
reinforc
individu
immun
repertoir
control
hiv
viraemia
clinic
trial
demonstr
approach
safe
transient
reduc
viral
load
increas
immun
cell
count
howev
suffici
produc
clinic
benefit
significantli
work
requir
improv
transduct
expans
haematopoiet
progenitor
cell
sinc
use
polymer
np
formul
rapidli
expand
polym
offer
greater
stabil
control
structur
drug
load
increas
opportun
highthroughput
synthesi
compar
lipidbas
system
better
qualiti
control
polym
also
adapt
specif
function
provid
stimulirespons
properti
includ
respons
ph
redox
enzym
light
cation
polym
show
greatest
promis
deliveri
sirna
electrostat
bind
condens
sirna
np
improv
cellular
uptak
howev
use
cation
polym
fine
balanc
membran
disrupt
result
toxic
membran
disrupt
result
transfect
synthet
natur
polym
explor
candid
must
nontox
nonimmunogen
noncarcinogen
ultim
degrad
clear
bodi
via
excret
multipl
polym
composit
architectur
investig
suitabl
sirna
deliveri
exampl
includ
block
copolym
diblock
triblock
polymer
micel
dendrim
star
polym
fig
subtl
differ
architectur
physicochem
properti
np
complex
ie
size
stiff
surfac
potenti
morpholog
hydrophob
signific
effect
vitro
vivo
deliveri
effici
thu
polym
composit
care
consid
design
deliveri
vehicl
clinic
trial
use
sirna
involv
polymer
carrier
system
first
target
deliveri
sirna
accomplish
human
use
complex
cyclodextrinbas
polym
transferrin
target
polyethylen
glycol
peg
stabilis
known
calando
pharmaceut
target
np
administ
intraven
treatment
solid
tumour
howev
phase
trial
termin
patient
discontinu
studi
due
advers
side
effect
mild
dosedepend
elev
serum
cytokin
also
measur
elev
transient
natur
peak
h
postinfus
return
baselin
h
anoth
phase
clinic
trial
conduct
drug
elut
loder
biodegrad
polymer
implant
surgic
place
tumour
design
slow
releas
sirna
therapeut
trial
treatment
local
advanc
pancreat
cancer
combin
chemotherapi
order
target
mutat
kra
gene
hallmark
pancreat
cancer
patient
studi
median
surviv
month
compar
median
surviv
month
treat
chemotherapi
success
complet
trial
pave
way
phase
iib
trial
schedul
begin
februari
clinicaltrialsgov
polym
poli
lactic
acid
pla
poli
glycol
acid
pga
polycaprolacton
pcl
copolym
poli
lactid
co
glycolid
plga
approv
fda
date
howev
polymer
np
gene
deliveri
system
approv
given
unknown
longterm
toxic
low
gene
transfect
effici
nanomateri
vivo
one
antivir
polymer
carrier
dynam
polyconjug
reach
clinic
trial
nevertheless
sever
vitro
vivo
model
demonstr
inhibit
viral
challeng
model
promis
candid
outlin
tabl
consist
amphipath
polym
shield
peg
revers
attach
target
ligand
one
dpc
combat
chronic
hbv
reach
phase
ii
clinic
trial
consist
two
synthet
modifi
cholesterolconjug
sirna
fig
coadminist
hepatocyt
target
peptid
nacetylglucosamin
nag
conjug
amphipath
membran
activ
polym
melittinlik
peptid
nagmlp
fig
compon
endocytos
respect
receptor
hepatocyt
fig
endosom
nag
compon
releas
allow
mlp
interact
endosom
membran
facilit
sirna
releas
concentr
mgkg
administ
healthi
volunt
iv
mgkg
patient
chronic
hbv
appear
well
toler
also
show
statist
signific
reduct
hbv
antigen
level
novemb
press
releas
arrowhead
pharmaceut
announc
trial
would
discontinu
favor
new
proprietari
subcutan
extrahepat
deliveri
system
dpc
sq
tm
fig
coadminist
modifi
cholesterolconjug
sirna
b
nagmlp
polym
c
compon
endocytos
respect
receptor
acid
endosom
nag
releas
mlp
abl
associ
disrupt
endosom
membran
allow
sirna
releas
cytoplasm
associ
risc
lead
hbv
rna
degrad
due
decis
regulatori
committe
halt
trial
primat
death
nonclin
toxicolog
studi
investig
herp
simplex
viru
hsv
repres
signific
problem
world
health
facilit
coinfect
hiv
chlamydia
syphili
polym
np
shown
promis
deliveri
agent
vivo
inhibit
hsv
exampl
steinbach
et
al
develop
plgabas
polymersirna
np
form
use
doubleemuls
solvent
evapor
techniqu
fig
first
step
sirna
target
protein
hsv
requir
cleavag
packag
viral
dna
act
hsv
receptor
bound
cation
polyamin
spermidin
form
polyplex
mix
poli
lacticcoglycol
acid
plga
initi
emuls
ad
polyvinyl
alcohol
pva
sonic
creat
second
emuls
dynam
light
scatter
dl
scan
electron
microscopi
sem
analysi
reveal
spheric
particl
approxim
nm
diamet
dose
respons
observ
vivo
studi
wherebi
mice
inocul
lethal
dose
topic
treat
plga
np
show
increas
surviv
day
untreat
mice
day
plga
nptreat
mice
studi
provid
promis
proofofconcept
valid
develop
topic
treatment
strategi
sirna
np
formul
number
research
group
also
begun
investig
applic
polymer
nanocarri
deliveri
vehicl
treatment
prevent
human
immunodefici
viru
hiv
whilst
explor
novel
applic
strategi
hiv
therapeut
femal
genit
tract
gu
cowork
develop
biodegrad
film
load
sirnacomplex
np
fig
np
complex
form
similarli
hsv
plga
particl
use
doubleemuls
solvent
evapor
initi
polyplex
polyethylenimin
pei
sirna
snare
protein
requir
hiv
particl
product
form
fig
protect
layer
plgapolyethylen
glycol
peg
ad
fig
surfac
np
functionalis
antihladr
antibodi
target
membran
hladr
immun
cell
vagin
mucosa
fig
embed
pva
kcarrageenan
glycerin
peg
film
fig
upon
applic
vitro
mucos
cocultur
model
film
degrad
free
np
cross
mucos
layer
epitheli
cell
deliveri
sirnacomplex
polym
hladr
cell
success
demonstr
signific
knockdown
express
fig
system
offer
promis
platform
administr
sirna
therapeut
mucosalin
organ
femal
genit
tract
addit
eszterha
et
al
har
commerci
avail
cation
polymer
transfect
agent
interferin
deliv
sirna
human
endometri
cervic
tissu
explant
ex
vivo
tissu
sampl
attenu
express
cell
receptor
observ
alongsid
protect
hiv
challeng
h
np
incub
vivo
trial
deliveri
murin
sirna
reduc
transcript
sever
day
demonstr
attenu
host
cell
proteinsin
case
receptor
involv
viral
entrycan
also
aid
attenu
viral
infect
sulfat
polysaccharid
chitosan
shown
antivir
properti
rang
virus
includ
hiv
block
viral
entri
viruscel
fusion
chitosan
also
use
deliveri
nucleic
acid
boyapal
et
al
develop
multifunct
chitosanlipid
nanocomplex
combin
antivir
activ
chitosan
deliveri
plasmid
express
four
antihiv
sirna
lipid
np
appli
cream
vagin
rhesu
monkey
day
infect
signific
decreas
viral
load
detect
day
infect
howev
control
monkey
viral
load
peak
plateau
day
formul
effect
deliv
plasmid
encod
sirna
provid
signific
protect
hiv
vitro
vivo
model
without
advers
effect
ge
et
al
report
inhibit
influenza
viru
mous
model
intraven
deliveri
peisirna
polyplex
nitrogen
phosphat
ratio
deliveri
lg
sirna
mice
h
prior
infect
result
reduct
lung
viru
titr
mice
despit
encourag
result
limit
number
deliveri
applic
use
pei
emerg
known
toxic
suitabl
therapeut
deliveri
work
perform
hinton
et
al
use
cation
triblock
polym
base
dimethylamino
ethyl
methacryl
dmaema
poli
ethylen
glycol
peg
synthesis
via
revers
additionfragment
chain
transfer
raft
polymeris
deliv
antiinfluenza
sirna
siantiflu
inhibit
viru
replic
chicken
embryo
fig
within
h
polym
clearli
internalis
cell
chorioallanto
membran
cam
site
influenza
replic
higher
magnif
becam
evid
polym
present
intracellular
vesicl
whilst
toxic
observ
cam
siantiflu
polym
complex
deliv
averag
log
decreas
viru
titr
observ
compar
pbsand
control
sirnatr
embryo
interest
polym
use
studi
also
shown
induc
interferon
respons
cam
cell
inject
without
sirna
allanto
fluid
egg
comparison
lower
level
ifn
respons
observ
polym
carri
sirna
effect
hypothesis
result
cell
respons
charg
polym
whilst
phenomenon
still
explor
induct
inf
respons
host
cell
base
polym
charg
may
benefici
har
treatment
viru
infect
characterist
sirnaload
cation
polym
np
must
care
tune
allow
bind
cell
entri
endosom
escap
whilst
minimis
toxic
consider
immun
stimul
also
import
demonstr
phase
clinic
trial
high
dose
polym
np
treatment
may
result
transient
increas
serum
cytokin
potenti
induc
helper
th
immun
respons
previou
work
gold
np
engin
np
system
enp
also
shown
particl
activ
nodlik
receptor
famili
pyrin
domaincontain
inflammasom
pathway
dangerassoci
molecular
pattern
damp
noninfecti
immun
respons
fig
activ
stimul
respons
result
interferon
ifn
c
express
hypothesis
depend
physicochem
properti
nanomateri
includ
np
size
shape
coat
helper
respons
import
antivir
immun
secret
ifn
cytokin
attract
lymphocyt
direct
immun
respons
helper
respons
also
import
b
cell
activ
high
level
antibodi
product
induc
cellular
memori
confer
longterm
protect
immun
immun
cell
includ
macrophag
dendrit
cell
larg
respons
activ
howev
cell
fibroblast
epitheli
cell
also
induc
respons
interestingli
common
adjuv
includ
alum
aluminium
salt
appear
work
inflammasom
pathway
follow
disrupt
lysosom
endocytosi
lipidbas
adjuv
lipopolysaccharid
induc
inflammasom
activ
pathogenassoci
molecular
pattern
recognis
foreign
antigen
tolllik
receptor
resid
cell
membran
therefor
polym
abl
induc
damp
respons
similar
adjuv
whilst
deliv
antivir
sirna
may
benefici
acut
antivir
treatment
approach
current
investig
polymerpeptidebas
vaccin
mrna
pdna
vaccin
rang
virus
howev
must
mind
type
effect
administr
longterm
treatment
strategi
induc
damp
respons
could
problemat
frequent
extens
stimul
high
level
antibodi
produc
deliveri
vehicl
could
also
lead
amplif
immun
respons
may
lead
danger
offtarget
side
effect
time
respons
may
also
contribut
reduc
effect
therapeut
exampl
rapid
clearanc
liposom
bloodstream
known
acceler
blood
clearanc
phenomenon
report
follow
repeat
treatment
therefor
fine
balanc
must
maintain
factor
dose
composit
deliveri
agent
frequenc
administr
order
achiev
maximum
effect
sirna
therapeut
mention
chemic
physic
paramet
polym
sirnabound
np
complex
substanti
influenc
tissu
target
cell
uptak
toxic
gene
silenc
abil
therapeut
agent
thu
essenti
identifi
import
correl
physicochem
properti
sirnapolym
complex
efficaci
viral
inhibit
vitro
vivo
comprehens
chemic
characteris
usual
achiev
use
combin
nuclear
magnet
reson
spectroscopi
chromatograph
techniqu
tool
accur
quantif
np
physic
paramet
eg
size
morpholog
stiff
surfac
charg
less
well
fig
damp
respons
uptak
np
cell
inflammasom
activ
endocytos
np
includ
b
uptak
highli
charg
particl
open
ion
channel
result
k
efflux
compens
charg
imbal
activ
cathepsin
b
c
cation
np
could
induc
proton
spong
effect
ruptur
lysosom
compart
lysosom
ruptur
releas
lysosom
content
eg
cathepsin
b
e
cathepsin
b
activ
f
produc
matur
g
convert
prointerleukin
il
matur
h
activ
cytokin
secret
attract
stimul
respons
defin
choic
avail
techniqu
confus
section
discuss
strength
weak
complementari
techniqu
avail
quantif
physic
paramet
accur
quantif
charg
densiti
polym
np
sirna
complex
import
high
complex
may
cytotox
low
may
insuffici
posit
charg
bind
cell
membran
hinder
endocytosi
zeta
potenti
zp
commonli
use
estim
surfac
charg
np
dispers
charg
particl
electrolyt
solut
form
electr
doubl
layer
edl
charg
ion
around
particl
fig
place
electr
field
charg
particl
move
toward
opposit
charg
electrod
electrophoresi
light
scatter
typic
use
determin
veloc
particl
undergo
electrophoresi
turn
relat
electr
potenti
plane
within
edl
zp
np
size
affect
abil
particl
undergo
cell
uptak
pathway
cell
uptak
occur
differ
hydrodynam
radiu
np
core
size
also
provid
insight
deliveri
effici
brief
overview
common
method
determin
size
polymer
np
dynam
light
scatter
dl
techniqu
wherebi
laser
pass
suspens
np
intens
scatter
light
measur
brownian
motion
particl
caus
fluctuat
detect
intens
use
estim
hydrodynam
radii
r
h
particl
via
stokeseinstein
equat
fig
popular
dl
particl
size
tool
stem
fact
quantit
result
larg
popul
np
solut
obtain
quickli
easili
due
short
timescal
requir
data
collect
min
timeresolv
studi
perform
furthermor
combin
dl
zp
instrument
allow
larg
proport
physic
np
characteris
perform
instrument
dl
number
limit
care
consid
perform
particl
size
measur
intens
scatter
light
sensit
presenc
adsorb
group
fluorophor
radiu
r
particl
solut
r
thu
colour
fluoresc
sampl
avoid
presenc
larg
particl
dust
contamin
caus
r
h
overestim
sampl
must
pure
homogen
nonaggreg
thu
timeconsum
potenti
damag
prepar
protocol
eg
extens
sonic
often
requir
prevent
underestim
particl
size
import
incid
photon
undergo
one
scatter
event
thu
polym
np
target
viruschalleng
cell
maximum
work
concentr
dl
often
lower
clinic
relev
concentr
import
interparticl
forc
may
affect
efficaci
miss
nanoparticl
track
analysi
nta
combin
laser
scatter
microscopi
np
track
determin
r
h
fig
nta
reli
ensembl
measur
show
increas
sensit
larger
particl
better
suit
measur
polydispers
sampl
estim
particl
concentr
higher
resolut
dl
particularli
use
case
polym
np
often
show
consider
variat
particl
size
due
molecular
weight
distribut
whilst
nta
provid
accur
measur
r
h
compar
dl
also
limit
nta
instrument
difficult
oper
less
autom
paramet
optimis
make
nta
measur
timeconsum
laborintens
concentr
rang
nta
like
dl
limit
howev
major
polymer
sirna
complex
polydispers
contain
multipl
popul
np
similar
r
h
nta
provid
greater
confid
particl
size
measur
fig
schemat
electr
doubl
layer
form
charg
particl
electrolyt
solut
electrophoresi
charg
particl
migrat
toward
electrod
slip
plane
mobil
static
ion
red
dash
line
establish
electr
potenti
plane
known
zeta
potenti
deviat
spheric
morpholog
seen
mani
polym
np
shown
affect
cell
uptak
microscopi
techniqu
sem
transmiss
electron
microscopi
atom
forc
microscopi
afm
offer
subnanomet
resolut
distinguish
shape
morpholog
individu
polym
complex
provid
true
nonhydrodynam
particl
size
fig
b
like
nanoscal
analyt
techniqu
limit
obviou
sem
tem
afm
particl
must
adsorb
solid
substrat
imag
may
affect
morpholog
addit
coat
metal
thin
film
heavi
metal
stain
uranyl
acet
often
requir
enhanc
contrast
em
may
alter
sampl
morpholog
introduc
imag
artefact
furthermor
electron
microscop
typic
oper
vacuum
requir
dehydr
np
imag
dehydr
avoid
use
cryosem
cryotem
howev
techniqu
expens
complex
requir
consider
user
expertis
environment
scan
electron
microscopi
esem
oper
reduc
vacuum
water
remain
liquid
phase
allow
investig
np
physiolog
environ
although
resolut
esem
typic
lower
sem
tap
mode
afm
well
suit
polym
np
morpholog
characteris
fig
b
oper
littl
sampl
prepar
fluid
environ
rel
eas
scan
speed
associ
typic
afm
experi
hz
make
techniqu
slow
howev
develop
highspe
afm
unit
oper
scan
speed
hz
higher
may
mean
slow
scan
rate
associ
afm
soon
thing
past
np
stiff
shown
theoret
experiment
larg
influenc
cell
uptak
potenti
endosom
escap
techniqu
monitor
forc
exert
static
oscil
afm
tip
substrat
use
mani
year
determin
stiff
materi
lack
spatial
resolut
make
difficult
quantifi
individu
np
recent
develop
includ
quantit
nanomechan
atom
forc
microscopi
qnmafm
enabl
map
mechan
properti
surfac
nanoscal
resolut
allow
stiff
individu
np
map
potenti
revolutionis
physic
characteris
polym
np
mode
oper
differ
slightli
among
manufactur
advanc
softwar
hardwar
gener
allow
measur
forc
afm
tip
record
everi
pixel
tip
raster
across
substrat
stiff
moduli
extract
forc
vs
distanc
curv
use
numer
algorithm
eg
sneddon
dmt
analysi
provid
nanoscal
map
stiff
fig
abil
routin
measur
mechan
properti
individu
np
use
qnmafm
enabl
greater
understand
stiff
mechan
properti
affect
cell
uptak
ideal
analysi
physicochem
properti
target
nanocarri
har
combin
techniqu
correl
physic
paramet
particl
size
stiff
surfac
charg
biolog
phenomena
cell
uptak
gene
silenc
use
basi
ration
design
futur
gener
polymer
deliveri
vehicl
fig
despit
initi
interest
sirna
antivir
therapeut
pharmaceut
compani
becom
increasingli
hesit
invest
new
research
space
given
limit
success
demonstr
clinic
trial
despit
limit
howev
research
around
new
polym
deliveri
vehicl
devic
highli
competit
field
continu
improv
innov
furthermor
report
recent
clinic
trial
suggest
sirna
therapi
may
also
effect
deliv
prophylact
rather
postexposur
therapeut
regimen
along
adjuvantlik
effect
np
carrier
new
avenu
applic
emerg
sirna
therapeut
whilst
current
research
around
sirna
deliveri
direct
toward
cancer
treatment
regim
highli
like
success
clinic
trial
rekindl
interest
sirna
antivir
therapeut
dynam
fastpac
global
economi
sirna
deliveri
strategi
still
hold
promis
combat
mani
world
persist
emerg
viral
diseas
